Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05273567 · ClinicalTrials.gov registry record · Phase 2
A Trial of Guanfacine-er for Cannabis Use Disorder
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT05273567 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 22 participants.
The verdict
NCT05273567, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The primary purpose of this study is to investigate the effect of guanfacine-ER on reductions in cannabis use and explore its effects on impulsivity and withdrawal through a hybrid in-person and virtual trial of treatment-seeking individuals with Cannabis Use Disorder (CUD), and assessing the feasibility of the virtual components of the study.
Interventions
- OTHER Placebo
- DRUG guanfacine-ER
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2022-06-01 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05273567
The ClinicalTrials.gov registry entry for NCT05273567 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05273567 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05273567 about?
NCT05273567 is a clinical study titled "A Trial of Guanfacine-er for Cannabis Use Disorder". The primary purpose of this study is to investigate the effect of guanfacine-ER on reductions in cannabis use and explore its effects on impulsivity and withdrawal through a hybrid in-person and virtual trial of treatment-seeking individuals with Cannabis Use Disorder (CUD), and assessing the feasib...
What is the current status of trial NCT05273567?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2022-06-01. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT05273567?
The interventions under investigation include: Placebo (OTHER), guanfacine-ER (DRUG).
Who is sponsoring clinical trial NCT05273567?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.